343 related articles for article (PubMed ID: 20938767)
21. Association between P1NP and bone strength in postmenopausal women treated with teriparatide.
Chen FP; Fu TS; Lin YC; Sung CM; Huang MH; Lin YJ
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):91-95. PubMed ID: 35181054
[TBL] [Abstract][Full Text] [Related]
22. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
23. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
24. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
25. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
26. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
27. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
[TBL] [Abstract][Full Text] [Related]
28. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
[TBL] [Abstract][Full Text] [Related]
29. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
32. Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Fahrleitner-Pammer A; Burr D; Dobnig H; Stepan JJ; Petto H; Li J; Krege JH; Pavo I
Bone; 2016 Aug; 89():16-24. PubMed ID: 27185100
[TBL] [Abstract][Full Text] [Related]
33. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
36. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
[TBL] [Abstract][Full Text] [Related]
37. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
38. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.
Hwang JS; Tu ST; Yang TS; Chen JF; Wang CJ; Tsai KS
Osteoporos Int; 2006; 17(3):373-8. PubMed ID: 16421647
[TBL] [Abstract][Full Text] [Related]
39. Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.
Sugimoto T; Nakamura T; Nakamura Y; Isogai Y; Shiraki M
Osteoporos Int; 2014 Mar; 25(3):1173-80. PubMed ID: 24108429
[TBL] [Abstract][Full Text] [Related]
40. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
